EVOLUS, INC. Interest Expense Nonoperating
EVOLUS, INC. (EOLS) reported Interest Expense Nonoperating of $4.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- EVOLUS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $4.17M, a 42.11% decline year-over-year.
- EVOLUS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $3.98M, a 9.97% decline year-over-year.
- EVOLUS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $3.98M, a 13.01% decline year-over-year.
- EVOLUS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $4.09M, a 14.06% decline year-over-year.
- EVOLUS, INC. interest expense nonoperating for fiscal 2025 was $19.69M, a 5.12% increase from fiscal 2024.
- EVOLUS, INC. interest expense nonoperating for fiscal 2024 was $18.73M, a 35.45% increase from fiscal 2023.
- EVOLUS, INC. interest expense nonoperating for fiscal 2023 was $13.83M, a 52.05% increase from fiscal 2022.
- EVOLUS, INC. interest expense nonoperating for fiscal 2022 was $9.10M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.17M 10-Q · filed 2026-08-05 | $8.15M 10-Q · filed 2026-08-05 | $12.13M derived: sum of 3 quarters · filed 2026-08-05 | $16.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.98M 10-Q · filed 2026-05-04 | $7.95M derived: sum of 2 quarters · filed 2026-05-04 | $12.05M derived: sum of 3 quarters · filed 2026-05-04 | $19.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $8.07M derived: sum of 2 quarters · filed 2026-03-03 | $15.28M derived: sum of 3 quarters · filed 2026-08-05 | $19.69M 10-K · filed 2026-03-03 |
| 2025-09-30 | $4.09M 10-Q · filed 2025-11-05 | $11.30M derived: sum of 2 quarters · filed 2026-08-05 | $15.72M 10-Q · filed 2025-11-05 | $20.29M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.21M 10-Q · filed 2026-08-05 | $11.62M 10-Q · filed 2026-08-05 | $16.20M derived: sum of 3 quarters · filed 2026-08-05 | $20.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.42M 10-Q · filed 2026-05-04 | $8.99M derived: sum of 2 quarters · filed 2026-05-04 | $13.75M derived: sum of 3 quarters · filed 2026-05-04 | $18.45M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $9.34M derived: sum of 2 quarters · filed 2026-03-03 | $14.03M derived: sum of 3 quarters · filed 2026-03-03 | $18.73M 10-K · filed 2026-03-03 |
| 2024-09-30 | $4.76M 10-Q · filed 2025-11-05 | $9.46M derived: sum of 2 quarters · filed 2025-11-05 | $14.16M 10-Q · filed 2025-11-05 | $18.24M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $4.70M 10-Q · filed 2025-08-05 | $9.40M 10-Q · filed 2025-08-05 | $13.47M derived: sum of 3 quarters · filed 2026-03-03 | $17.26M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $4.70M 10-Q · filed 2025-05-07 | $8.78M derived: sum of 2 quarters · filed 2026-03-03 | $12.56M derived: sum of 3 quarters · filed 2026-03-03 | $15.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.86M derived: sum of 2 quarters · filed 2026-03-03 | $11.04M derived: sum of 3 quarters · filed 2026-03-03 | $13.83M 10-K · filed 2026-03-03 |
| 2023-09-30 | $3.79M 10-Q · filed 2024-11-06 | $6.97M derived: sum of 2 quarters · filed 2024-11-06 | $9.76M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $3.18M 10-Q · filed 2024-07-31 | $5.97M 10-Q · filed 2024-07-31 | ||
| 2022-12-31 | $9.10M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |